KHẢO SÁT ĐẶC ĐIỂM LÂM SÀNG, TÚI PHÌNH VÀ ĐA HÌNH GEN CYP2C19*2, CYP2C19*3 Ở BỆNH NHÂN PHÌNH MẠCH MÁU NÃO ĐIỀU TRỊ BẰNG STENT CHUYỂN DÒNG TẠI BỆNH VIỆN ĐA KHOA QUỐC TẾ S.I.S CẦN THƠ

Abstract

Background: Preliminary study evaluates the CYP2C19 gene, which has phenotypes affecting clopidogrel metabolism in patients with cerebral aneurysms with transgenic stents. Objectives: Identify gene polymorphism CYP2C19*2, CYP2C19*3 in brain aneurysm patients used flow diversion with stents by Digital subtraction angiography at S.I.S Can Tho International Hospital. Materials and methods: Cross-sectional study on 30 brain aneurysm patients put stents for flow diversion by Digital subtraction angiography at S.I.S Can Tho International Hospital. Results: 46.67% of patients with gene CYP2C19*2, CYP2C19*3 have the reduced metabolic function of Clopidogrel. Among them, the patients with gene CYP2C19*2 account for the most 85.71%. The phenotype homozygous CYP2C19 accounts for 28.57%, and the remaining is reduced functional heterozygous gene. Conclusion: The percentage of patients carrying gene CYP2C19*2, CYP2C19*3 is high and the allele heterozygous phenotype occurs the most among the patients. Screening for gene polymorphism CYP2C19*2, CYP2C19*3 is important for Clopidogrel dose adjustment in brain aneurysm patients carrying gene against Clopidogrel treated by stenting for flow diversion.